IFN-γ在肿瘤免疫检查点抑制剂治疗中的研究进展

doi:10.11904/j.issn.1002-3070.2024.05.008

摘要/Abstract

摘要： 免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs)主要通过解除肿瘤免疫抑制作用促进抗肿瘤免疫。干扰素-γ(Interferon-γ,IFN-γ)在增加肿瘤抗原提呈、诱导免疫细胞浸润和直接促进肿瘤凋亡方面发挥了重要作用,成为提升免疫治疗疗效的关键因素。IFN-γ的信号通路异常及自身的促肿瘤作用是引发ICIs治疗耐药的关键机制。免疫治疗通过与IFN-γ或IFN-γ诱导剂联用,能够有效恢复MHC-I的呈递能力、增加免疫细胞浸润,进而提高免疫治疗效果。此外,国内外学者通过使IFN-γ信号通路正常化、将ICIs与JAKi联用等方法在临床试验中取得了一定疗效。本综述主要介绍了IFN-γ在肿瘤ICIs治疗中发挥的作用,为逆转ICIs耐药的潜在治疗策略提供方向,进一步为临床应用提供理论基础。

关键词: IFN-γ, 恶性肿瘤, 免疫检查点抑制剂, 治疗耐药

Abstract: Immune checkpoint inhibitors(ICIs)mainly promote anti-tumor immunity by relieving tumor immune suppression.Interferon-γ(IFN-γ)plays an important role in increasing tumor antigen presentation,inducing immune cell infiltration,and directly inducing tumor cell apoptosis,becoming a key factor in improving the efficacy of immunotherapy.The abnormal signaling pathway of IFN-γ and its own effect on promoting tumor are the key mechanisms that trigger resistance to ICIs therapy.Immunotherapy,when combined with IFN-γ or IFN-γ inducers,can effectively restore the presentation ability of MHC-I,increase immune cell infiltration,and thus improve the efficacy of immunotherapy.In addition,domestic and foreign scholars have achieved certain therapeutic effects on clinical trials by normalizing the IFN-γ signaling pathway and combining ICIs with JAKi.This review mainly introduces the role of IFN-γ in the treatment of tumor ICIs,providing direction for potential treatment strategies to reverse ICIs resistance and further providing theoretical basis for clinical application.

Key words: IFN-γ, Cancer, Immune checkpoint inhibitors, Therapeutic resistance

中图分类号:

何佳颖, 朱津丽, 贾凯旋, 杨佩颖. IFN-γ在肿瘤免疫检查点抑制剂治疗中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(5): 330-335.

HE Jiaying, ZHU Jinli, JIA Kaixuan, YANG Peiying. Research progress of IFN-γ in the treatment of tumor immune checkpoint inhibitors[J]. Journal of Practical Oncology, 2024, 38(5): 330-335.

参考文献

1 Rui R,Zhou L,He S.Cancer immunotherapies:advances and bottlenecks[J].Front Immunol,2023,14:1212476.
2 Marei HE,Hasan A,Pozzoli G,et al.Cancer immunotherapy with immune checkpoint inhibitors(ICIs):potential,mechanisms of resistance,and strategies for reinvigorating T cell responsiveness when resistance is acquired[J].Cancer Cell Int,2023,23(1):64.
3 Gocher AM,Workman CJ,Vignali D.Interferon-gamma:teammate or opponent in the tumour microenvironment?[J].Nat Rev Immunol,2022,22(3):158-172.
4 Seiwert TY,Burtness B,Mehra R,et al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-012):an open-label,multicentre,phase 1b trial[J].Lancet Oncology,2016,17(7):956-965.
5 Muro K,Chung HC,Shankaran V,et al.Pembrolizumab for patients with PD-L1-positive advanced gastric cancer(KEYNOTE-012):a multicentre,open-label,phase 1b trial[J].Lancet Oncology,2016,17(6):717-726.
6 Fehrenbacher L,Spira A,Ballinger M,et al.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer(POPLAR):a multicentre,open-label,phase 2 randomised controlled trial[J].Lancet,2016,387(10030):1837-1846.
7 Reschke R,Gajewski TF.CXCL9 and CXCL10 bring the heat to tumors[J].Sci Immunol,2022,7(73):6509.
8 Reschke R,Enk AH,Hassel JC.Chemokines and cytokines in immunotherapy of melanoma and other tumors:from biomarkers to therapeutic targets[J].Int J Mol Sci,2024,25(12):6532.
9 Fang S,Xu T,Xiong M,et al.Role of immune response,inflammation,and tumor immune response-related cytokines/chemokines in melanoma progression[J].J Invest Dermatol,2019,139(11):2352-2358.
10 Baer C,Squadrito ML,Laoui D,et al.Suppression of microRNA activity amplifies IFN-gamma-induced macrophage activation and promotes anti-tumour immunity[J].Nat Cell Biol,2016,18(7):790-802.
11 Zhang Y,Ma S,Li T,et al.ILC1-derived IFN-gamma regulates macrophage activation in colon cancer[J].Biol Direct,2023,18(1):56.
12 Liu C,Chikina M,Deshpande R,et al.Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8(+)T cell-derived interferon-gamma[J].Immunity,2019,51(2):381-397.
13 Zhou F.Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation[J].Int Rev Immunol,2009,28(3-4):239-260.
14 Rimando JC,Chendamarai E,Rettig MP,et al.Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells[J].Blood,2023,141(14):1718-1723.
15 Kammertoens T,Friese C,Arina A,et al.Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression[J].Nature,2017,545(7652):98-102.
16 Zhang Z,Zhang Y,Xia S,et al.Gasdermin E suppresses tumour growth by activating anti-tumour immunity[J].Nature,2020,579(7799):415-420.
17 Yu L,Huang K,Liao Y,et al.Targeting novel regulated cell death:ferroptosis,pyroptosis and necroptosis in anti-PD-1/PD-L1 cancer immunotherapy[J].Cell Prolif,2024,57(8):e13644.
18 Gao J,Shi LZ,Zhao H,et al.Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to Anti-CTLA-4 therapy[J].Cell,2016,167(2):397-404.
19 Overacre-Delgoffe AE,Chikina M,Dadey RE,et al.Interferon-gamma drives Treg fragility to promote anti-tumor immunity[J].Cell,2017,169(6):1130-1141.
20 Shin DS,Zaretsky JM,Escuin-Ordinas H,et al.Primary resistance to PD-1 blockade mediated by JAK1/2 mutations[J].Cancer Discov,2017,7(2):188-201.
21 Zaretsky JM,Garcia-Diaz A,Shin DS,et al.Mutations associated with acquired resistance to PD-1 blockade in melanoma[J].N Engl J Med,2016,375(9):819-829.
22 Wong CW,Huang YY,Hurlstone A.The role of IFN-gamma-signalling in response to immune checkpoint blockade therapy[J].Essays Biochem,2023,67(6):991-1002.
23 Song M,Ping Y,Zhang K,et al.Low-dose IFNgamma induces tumor cell stemness in tumor microenvironment of non-small cell lung cancer[J].Cancer Res,2019,79(14):3737-3748.
24 Benci JL,Xu B,Qiu Y,et al.Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade[J].Cell,2016,167(6):1540-1554.
25 Stifter K,Krieger J,Ruths L,et al.IFN-gamma treatment protocol for MHC-I(lo)/PD-L1(+)pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential[J].J Immunother Cancer,2020,8(2):e000692.
26 Zhang M,Huang L,Ding G,et al.Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer[J].J Immunother Cancer,2020,8(1):e000308.
27 Zibelman M,MacFarlane AT,Costello K,et al.A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors[J].Nat Commun,2023,14(1):4513.
28 Garris CS,Arlauckas SP,Kohler RH,et al.Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12[J].Immunity,2018,49(6):1148-1161.
29 Greaney SK,Algazi AP,Tsai KK,et al.Intratumoral plasmid IL12 electroporation therapy in patients with advanced melanoma induces systemic and intratumoral T-cell responses[J].Cancer Immunol Res,2020,8(2):246-254.
30 Algazi AP,Twitty CG,Tsai KK,et al.Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma[J].Clin Cancer Res,2020,26(12):2827-2837.
31 Toney NJ,Gatti-Mays ME,Tschernia NP,et al.Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12[J].Int Immunopharmacol,2023,116:109736.
32 Du W,Hua F,Li X,et al.Loss of optineurin drives cancer immune evasion via palmitoylation-dependent IFNGR1 lysosomal sorting and degradation[J].Cancer Discov,2021,11(7):1826-1843.
33 Zhang Y,Wang M,Ye L,et al.HKDC1 promotes tumor immune evasion in hepatocellular carcinoma by coupling cytoskeleton to STAT1 activation and PD-L1 expression[J].Nat Commun,2024,15(1):1314.
34 Du WY,Masuda H,Nagaoka K,et al.Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice[J].Gastric Cancer,2024,27(5):971-985.
35 Lynce F,Stevens LE,Li Z,et al.TBCRC 039:a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer[J].Breast Cancer Res,2024,26(1):20.
36 Munster P,Iannotti N,Cho DC,et al.Correction:combination of itacitinib or parsaclisib with pembrolizumab in patients with advanced solid tumors:a phase I study[J].Cancer Res Commun,2024,4(3):785.
37 Mathew D,Marmarelis ME,Foley C,et al.Combined JAK inhibition and PD-1 immunotherapy for non -small cell lung cancer patients[J].Science,2024,384(6702):1314.
38 Angelicola S,Ruzzi F,Landuzzi L,et al.IFN-gamma and CD38 in hyperprogressive cancer development[J].Cancers(Basel),2021,13(2):309.
39 Liang X,Gao H,Xiao J,et al.Abrine,an IDO1 inhibitor,suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma[J].Front Immunol,2023,14:1185985.
40 Long GV,Dummer R,Hamid O,et al.Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma(ECHO-301/KEYNOTE-252):a phase 3,randomised,double-blind study[J].Lancet Oncol,2019,20(8):1083-1097.
41 Necchi A,Van der Heijden MS,Trukhin D,et al.Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma:results from the ECHO-307/KEYNOTE-672 study[J].BMC Cancer,2024,23(Suppl 1):1252.
42 Labadie BW,Bao R,Luke JJ.Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis[J].Clin Cancer Res,2019,25(5):1462-1471.
43 Wong CW,Evangelou C,Sefton KN,et al.PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNgamma-driven acquired resistance in preclinical cancer models[J].Nat Commun,2023,14(1):5983.
44 Fenton SE,Zannikou M,Ilut L,et al.Targeting ULK1 decreases IFNgamma-mediated resistance to immune checkpoint inhibitors[J].Mol Cancer Res,2023,21(4):332-344.

[1]	庞琬莹, 安静, 刘兆良. TRIM24在乳腺癌内分泌治疗耐药中的作用及机制研究[J]. 实用肿瘤学杂志, 2024, 38(6): 402-409.
[2]	陈茂森, 陈杨, 石青萍, 邵英, 唐娴, 任思颖, 文洪梅. 2020年云南省恶性肿瘤发病和死亡分析[J]. 实用肿瘤学杂志, 2024, 38(5): 283-288.
[3]	苏锋, 梁磊, 邓英, 张同蕾, 王艳平. 2016—2020年陕西省安康市恶性肿瘤流行特征和变化趋势分析[J]. 实用肿瘤学杂志, 2024, 38(5): 300-305.
[4]	韩晶, 关泉林. 肿瘤相关中性粒细胞在免疫检查点抑制剂耐药中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(5): 349-354.
[5]	刘丽莉, 张雪云, 张雷. 2020—2022年第一师阿拉尔市恶性肿瘤发病分析[J]. 实用肿瘤学杂志, 2024, 38(4): 246-253.
[6]	钟女娟, 马晶昱, 许志达. 2019年福建省福清市恶性肿瘤发病与死亡情况及2015—2019年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(1): 1-6.
[7]	赵璐, 张正凤, 王大臻, 杨柳, 刘泽, 娄长杰. 免疫治疗在实体瘤中的应用现状[J]. 实用肿瘤学杂志, 2024, 38(1): 55-61.
[8]	程锦, 王玮. 维甲酸诱导蛋白在消化系统恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 502-506.
[9]	赵世博, 陈永峰, 黎惠怡, 符爱珍. Agrin参与恶性肿瘤发生发展的研究现状[J]. 实用肿瘤学杂志, 2023, 37(6): 507-512.
[10]	宋述铭, 李改琴, 张黎峰, 许凯, 毛雯靖, 张光辉. 新疆医科大学附属肿瘤医院2010—2020年恶性肿瘤住院患者流行病学分析[J]. 实用肿瘤学杂志, 2023, 37(5): 389-394.
[11]	刘远霖, 冯立. miR-192-5p在恶性肿瘤中作用机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 439-442.
[12]	文洪梅, 陈杨, 石青萍, 朱云芳, 任思颖, 唐娴, 邵英, 伍福仙, 李云飞. 2018年云南省肿瘤登记地区恶性肿瘤的发病与死亡分析[J]. 实用肿瘤学杂志, 2023, 37(4): 293-300.
[13]	李福程, 贾斯媛, 巴玉玲, 罗丹利, 肖敏. 免疫检查点抑制剂在早期乳腺癌新辅助治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(4): 367-371.
[14]	龙朝恋, 李琨, 刘子臣, 张娜娜, 车南颖. 非小细胞肺癌程序性死亡配体-1表达与临床病理特征和常见驱动基因变异的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 117-122.
[15]	杨建华, 罗赛美, 龙欣甜, 李蔚, 杨璧榕, 余龙涛, 张腾, 文洪梅. 2017年云南省肿瘤登记地区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2023, 37(1): 6-10.